A
Alcista
Alcista · 25%HRMY
$52.23
Precio del escenario
$38.310
-0.387 (-1.01%)Al cierre
Loading chart…
- Máximo
- 38.930
- Apertura
- 38.580
- Precio medio ponderado por volumen
- 38.46
- Volumen
- 1.06M
- Capitalización
- 1.79B
- Mínimo
- 38.130
- Importe
- 40.86M
- EV/EBITDA, TTM
- 4.22
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Análisis de IA of Harmony Biosciences Holdings Inc (HRMY)
ComprarHarmony Biosciences appears to be a good buy right now, trading at $37.95 with a forward P/E of 10.06, which is attractive compared to its growth potential. The recent drop of over 5% due to a CEO change may present a buying opportunity, especially as the company reaffirmed its revenue guidance of $1 billion to $1.04 billion for Wakix, indicating strong fundamentals. However, the RSI is at 38.73, suggesting the stock is nearing oversold territory, which could lead to a rebound.
Métricas de valoración
El PER previsto actual de Harmony Biosciences Holdings Inc (HRMY) es 10.06, frente a su media de 5 años de 14.37.
Escenarios de precio de Alphio AI para HRMY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con HRMY en cartera
Cronología de eventos
Noticias
5.010-13FoolHarmony Biosciences Announces CEO Change, Shares Drop Over 5%
6.008-26CNBCLatest Ratings and Outlook from Wall Street
8.008-04NASDAQ.COMEnphase Energy and Innovex International Show High Options Trading Volume
9.508-04seekingalphaHarmony Biosciences Q2 Earnings Exceed Expectations
9.508-04NASDAQ.COMHarmony Biosciences Reports Significant Q2 Earnings Growth
Preguntas frecuentes sobre HRMY, respondidas por Alphio AI
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Harmony Biosciences appears to be a good buy right now, trading at $37.95 with a forward P/E of 10.06, which is attractive compared to its growth potential. The recent drop of over 5% due to a CEO change may present a buying opportunity, especially as the company reaffirmed its revenue guidance of $1 billion to $1.04 billion for Wakix, indicating strong fundamentals. However, the RSI is at 38.73, suggesting the stock is nearing oversold territory, which could lead to a rebound.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.